Mbis Presentation University
•Download as PPT, PDF•
1 like•416 views
The document discusses Mass CONNECT, a program that aims to leverage industry networks to advance translational research and bridge the "translation gap" between academic discoveries and early-stage commercial opportunities. The program provides mentoring, industry screening of technologies, and connections to proven industry advisors and networks to accelerate promising opportunities and increase the throughput of technologies out of academic offices. It describes the ideal profiles of technologies and investigators that would benefit from the program.
Recommended
More Related Content
What's hot
What's hot (17)
Viewers also liked
Similar to Mbis Presentation University
Similar to Mbis Presentation University (20)
Mbis Presentation University
- 1. Mass CONNECT Leveraging industry networks to advance translational research
- 2. The goal of translational medicine… Industry AMC/Univ Bench Bedside Bench Late-preclinical & Preclinical dev Clinical development Clinical trials Bedside
- 3. Pharma’s predicament 10 20 30 40 50 60 40 30 20 10 1995 2000 2005 50 NMEs and Biologics Approved R&D Spending (US$ Billions) R&D expenditures Approvals Sources: FDA/CDER, PhRMA, PricewaterhouseCoopers Note: R&D spending from non-PhRMA companies not available Courtesy of Ted Torphy, JNJ presented at Massbio Pharma Days
- 4. Translating research to products Value $ Invention = data, tools, IP, Know-How RO1 funding enabled research “ Applied” research Basic research Research progress Phase II-Proof of concept Proof of principle FIM Animal disease model Translation gap
- 12. Accelerating proof-of-concept to partnerships
- 18. You are cordially invited to apply for participation in MassCONNECT. http://www.massbio.org/membership/massconnect Deadline April 16 th , 2010 Have questions? Contact Imran Nasrullah, Chief Business Officer at MassBio, at 617-674-5151.
- 19. Back up slides
Editor's Notes
- The holy grail of medical research is getting the latest discoveries translated into products that can treat patients at the bedside- and conversely, observations made in the clinic can guide research at the bench- what we call bench to bedside. But a major component necessary to this is biotechnology and pharma’s contribution in the development of your ideas into real products..
- And pharma has a real predicament, for the last 15 years, pharma has spent more money and yielded less innovative medicines year on year since 1995. Pharmas real problem is that it cannot maintain its own growth as demanded by Wall Street Wall Street demands at least 10% returns each year from Pharma The demand to find new blockbusters to sustain such returns creates incredible pressures to find new blockbusters; especially in the face of looming patent cliffs But Pharma’s innovation track record is dismal as witnessed by the number of NMEs Consider Lipitor, in mid year 2008, its global sales were $12B Next year’s return needs to be $1.2B A new product needs to bring in $1.2B to keep EPS up
- So Pharma needs to solve its pipeline problem and it doesn’t know how Now I don’t expect you to have sympathy for Wall Street or Big Pharma for that matter, But, your interest should lie in their welfare because they are means by which delivery of medicines to the market occurs; and the conduit for product development and sales. To translate the research discoveries, external dollars are needed and networks are needed to turn ideas into products. R01 grants are not designed for product development There is a gap in dollars to fund such innovation
- The crux of the problem: There is a lot of great technologies here in the laboratories that will likely never see the light of day for a host of reasons - MassCONNECT overcomes the through put issue through the power of distributive tasking! The other major issue is because of low connectivity with industry. Poor networks of expertise, funding, and industry leadership; Inabiliy to effectively convert accomplishments achieved in the academic labs to the parlance of early stage pipeline opportunity; impedes transfer of value between academia and biotech/pharma; We create a bridge between academic researchers and industry to get you to speak the same language they do. By speaking the same language you create opportunities to advance innovation whether through licensing, or company start-up
- MassCONNECT accelerates the process! We are looking for the acorns that can someday turn to oak trees. Because drug development in purely a numbers game, we have to increase the throughput of innovative ideas to create more shots on goal That is, by bringing industry experts to review and screen many opportunities, we can sift through much more than the academic institution itself.
- Now some of you may ask yourself, how does industry or investor look at my stuff, so I thought I would provide you with a VCs quick and dirty guide… Unlike clinical proof of concept, here what is merited is technical or scientific proof of concept. In vivo data from animal models- having data from multiple species even more convincing. Platform capability- the ability to generate multiple therapeutics/diagnostics Multiples- favors a company Single – out license to pharma Highlights a big point: not everything is suitable towards creating a company around the asset, it may be that outlicensing is the right option – in which case our job is to increase the license value through the same mentoring process.
- Through our network, we will put you in contact with drug development entrepreneurs, for example BridgeGap which actually puts money in to develop an asset to value inflection points. Connect you to MassCHALLENGE Mass Life Science Center And other resources
- M&A rewards Wall Street, but it does little else to create productive, innovative drugs that will drive the growth demands. If you have a shallow pipeline, why would you acquire another company with an equally shallow pipeline, facing the same patent cliff you are? Consider if you took just 1% of the billions of dollars transacted in these M&As and used that money to seed early stage technology and emerging biotechnology, i.e. placing a lot of small bets, you would stand to gain from just one opportunity that pays back the risk of loss for all the other bets you made. Some companies are catching on, like Novartis, which has produced an option fund whose task is to place a lot of little bets to translate research by funding very early stage companies. Academia’s problem is that research funding is great for proving scientific hypotheses, but it is not being utilized to advance such advancement into real clinical solutions. You need dollars, guidance, and industry networks to advance your discoveries.